Information  X 
Enter a valid email address

HutchisonChnMedtechLtdUSD0.10 (HCM)

Date Time Source Announcement
26 May 2020 7:00 am
RNS
Chi-Med and BeiGene Enter Clinical Collaboration
14 May 2020 7:00 am
RNS
Clinical Data to be Presented at ASCO20
11 May 2020 4:41 pm
RNS
Second Price Monitoring Extn
  4:36 pm
RNS
Price Monitoring Extension
  7:00 am
RNS
Chi-Med to Attend Upcoming Investor Conferences
29 Apr 2020 11:45 am
RNS
Grant of Share Options under Share Option Scheme
27 Apr 2020 2:00 pm
RNS
Result of AGM
22 Apr 2020 9:00 am
RNS
Virtual Presentations of Surufatinib at AACR
21 Apr 2020 11:30 am
RNS
Grant of LTIP Awards and Share Options
17 Apr 2020 7:00 am
RNS
Surufatinib Granted FDA Fast Track Designations
31 Mar 2020 7:04 am
RNS
China Phase II trial initiation in mesothelioma
25 Mar 2020 7:00 am
RNS
Annual Financial Report
09 Mar 2020 7:00 am
RNS
Vesting of awards under Long Term Incentive Plan
03 Mar 2020 2:18 pm
RNS
Form-20F Publication
  12:15 pm
RNS
Final Results and Clinical Update
25 Feb 2020 7:00 am
RNS
Notice of Results
10 Feb 2020 7:00 am
RNS
Phase II Savolitinib / Imfinzi? Combination Data
06 Feb 2020 4:35 pm
RNS
Price Monitoring Extension
  7:20 am
RNS
Issue of Equity
04 Feb 2020 4:40 pm
RNS
Second Price Monitoring Extn
  4:35 pm
RNS
Price Monitoring Extension
31 Jan 2020 7:00 am
RNS
Notice of Results
29 Jan 2020 7:25 am
RNS
Holding(s) in Company
23 Jan 2020 7:35 am
RNS
Pricing of US$110 Million Public Offering of ADSs
22 Jan 2020 7:00 am
RNS
Chi-Med Announces Proposed Offering of ADSs
20 Jan 2020 10:40 am
RNS
Positive SANET-p Phase III Clinical Trial Results
13 Jan 2020 7:00 am
RNS
Chi-Med Starts Surufatinib+PD-1 Ph2 Combo Trial
06 Jan 2020 7:04 am
RNS
Chi-Med to Present at JP Morgan Conference
31 Dec 2019 7:00 am
RNS
Block Listing Six Monthly Return
  7:00 am
RNS
Total Voting Rights
20 Dec 2019 7:00 am
RNS
Surufatinib Granted Priority Review in China
12 Dec 2019 8:57 am
RNS
Grant of share options
29 Nov 2019 8:56 am
RNS
Total Voting Rights
28 Nov 2019 7:00 am
RNS
Elunate? Included in China NRDL
25 Nov 2019 7:47 am
RNS
Chi-Med Highlights Presentations at 2019 ESMO Asia
  7:00 am
RNS
Surufatinib granted FDA orphan drug designation
11 Nov 2019 7:00 am
RNS
Surufatinib China NDA acceptance
17 Oct 2019 7:26 am
RNS
Chi-Med Ph II gastric cancer data for Savolitinib
10 Oct 2019 10:22 am
RNS
Grant of share options under share option scheme
  9:00 am
RNS
Innovent and Chi-Med Expand Global Collaboration
04 Oct 2019 7:11 am
RNS
Chi-Med Phase I/Ib Trial of HMPL-523 in Lymphoma
03 Oct 2019 8:26 am
RNS
Holding(s) in Company
30 Sep 2019 1:49 pm
RNS
Holding(s) in Company
  12:11 pm
RNS
Holding(s) in Company
  7:00 am
RNS
Chi-Med Surufatinib Phase III data at ESMO
  7:00 am
RNS
Total Voting Rights
25 Sep 2019 7:00 am
RNS
Chi-Med Presents SANET-ep Phase III data at ESMO
18 Sep 2019 7:00 am
RNS
Chi-Med Highlights Presentations at 2019 CSCO
03 Sep 2019 7:19 am
RNS
Chi-Med to present at MS conference
  7:00 am
RNS
Chi-Med initiates Phase I trial
30 Aug 2019 7:00 am
RNS
Total Voting Rights
23 Aug 2019 7:00 am
RNS
Start of Clinical Trial in China
20 Aug 2019 7:48 am
RNS
Holding(s) in Company
30 Jul 2019 10:48 am
RNS
TR-1: Form for notification of major holdings
  7:00 am
RNS
2019 Interim Results and Clinical Programs Update
10 Jul 2019 4:35 pm
RNS
Price Monitoring Extension
03 Jul 2019 8:02 am
RNS
TR-1: Form for notification of major holdings
  7:00 am
RNS
Chi-Med to Announce 2019 Half-Year Results
  7:00 am
RNS
TR-1: Form for notification of major holdings
 
Headlines
Top categories
Company finder
Forthcoming announcements

a d v e r t i s e m e n t